Biotech unicorn Moderna Therapeutics baffled its peers last month when it raised $500 million in a seventh round of venture financing. How, the question went, did the company sell investors on a $7.5 billion valuation despite outstanding questions about its science?
STAT obtained Moderna’s investor slide deck, one in which the company predicts billion-dollar futures for drugs only tested in mice and argues its vaccines business can bring in $15 billion in annual revenue.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
I did not find the full slide deck as mentioned in the article. Please share if you have it.
The full deck is embedded at the bottom of the article.
Pat Skerrett
STAT
Sounds like investors are getting either stupid or they have too much capital to throw away. Investing on a dec of slide which is 100000% based upon assumptions, not science and data.